hVIVO (LON:HVO) Stock Price Down 9.3% – Time to Sell?

hVIVO plc (LON:HVO) shares dropped 9.3% during trading on Thursday . The company traded as low as GBX 8.30 and last traded at GBX 8.30. Approximately 3,446,697 shares traded hands during mid-day trading, a decline of 2% from the average daily volume of 3,530,541 shares. The stock had previously closed at GBX 9.15.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HVO. Shore Capital Group reissued a “buy” rating on shares of hVIVO in a report on Wednesday. Stifel Nicolaus reaffirmed a “hold” rating and set a GBX 10 target price on shares of hVIVO in a report on Wednesday, April 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of GBX 15.

hVIVO Trading Down 10.0%

The company’s fifty day simple moving average is GBX 7.96 and its 200-day simple moving average is GBX 6.87. The firm has a market capitalization of £56.71 million, a PE ratio of 10.70 and a beta of 1.67. The company has a debt-to-equity ratio of 38.75, a current ratio of 1.63 and a quick ratio of 1.16.

hVIVO (LON:HVO) last released its earnings results on Wednesday, April 15th. The company reported GBX (0.87) EPS for the quarter. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.The company had revenue of GBX 4,677 million for the quarter. As a group, sell-side analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.